Skip to main content
. 2008 Oct 10;26(29):4708–4713. doi: 10.1200/JCO.2007.15.9566

Fig 3.

Fig 3.

(A) Preferential suppression of soluble vascular endothelial growth factor receptor (sVEGFR) −2 and sVEGFR-3 by axitinib in patients with thyroid cancer. (B) Percentage change in calcitonin from baseline. (C) Percentage change in thyroglobulin from baseline. PD, progressive disease; SD, stable disease; PR, partial response.